BriaCell Therapeutics Cor... (BCTX)
NasdaqCM: BCTX
· Real-Time Price · USD
3.38
-0.03 (-0.88%)
At close: Aug 13, 2026, 12:55 PM
BriaCell Therapeutics Corp. (BCTX) Stock Price, Analysis & Data
-0.88% (1D)
| Bid | 2.51 |
| Market Cap | 29.41M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -30.68M |
| Beta | 1.52 |
| EPS (ttm) | -0.84 |
| PE Ratio (ttm) | n/a |
| Forward PE | -8.67 |
| P/B (ttm) | 1.02 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 4.41 |
| Volume | 42,691 |
| Avg. Volume (20D) | 202,025 |
| Open | 3.42 |
| Previous Close | 3.41 |
| Day's Range | 3.37 - 3.52 |
| 52-Week Range | 2.60 - 14.68 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BCTX
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an i...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 14, 2012
Employees n/a
Stock Exchange NasdaqCM
Ticker Symbol BCTX
Website https://briacell.com
Financial Performance
In 2024, BriaCell Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -4.79M, a decrease of -76.4%.
Financial StatementsEarnings Surprise
BriaCell Therapeutics has released their quarterly earnings on Oct 15, 2025:
Page 1 of 2